Lilly gains panel's backing to expand Cymbalta use

Back to TopCommentsE-mailPrintBookmark and Share

Eli Lilly and Co., the drugmaker whose top three products face generic competition within three years, won a U.S. panel’s backing to expand use of the antidepressant Cymbalta in chronic knee and back pain.

Outside advisers to the Food and Drug Administration voted 8-6 Thursday in Bethesda, Md., in favor of a broader use of Cymbalta on the basis of studies in lower back pain and osteoarthritis of the knee. The FDA usually follows its panels’ recommendations, though it isn’t required to do so.

Lilly needs revenue growth from aging products as new drugs struggle to reach the market. Annual revenue from Cymbalta, the company’s second-biggest seller, may increase by more than $500 million, or 16 percent, with approval for the millions of Americans with chronic back or knee pain, according to Seamus Fernandez, an analyst at Leerink Swann & Co. in Boston.

“I think it will be a very useful drug for a significant number of patients,” said panel chairman Jeffrey Kirsch, chair of the Department of Anesthesiology and Perioperative Medicine at the Oregon Health & Science University in Portland.

Sales of Cymbalta were $3.07 billion last year, accounting for 14 percent of Lilly’s revenue. The drug is scheduled to lose U.S. patent protection in 2013, along with the insulin Humalog, which ranks third in revenue. Top-selling Zyprexa, an antipsychotic, faces generic competition in 2011.

Lilly asked for broad approval in chronic pain in the second quarter of 2008 before withdrawing the application after the FDA raised concerns about study design and statistical methodology. The application was resubmitted in June 2009. An advisory panel review initially slated for January was canceled so regulators could have more time to consider new information pertaining to the drug’s “benefit-risk balance” in pain.

FDA officials said Thursday they aren’t comfortable generally recommended Cymbalta for all types of chronic pain and will instead consider approval for “musculoskeletal pain.”

“This is a fairly narrow broad indication” for Lilly, Bob Rappaport, head of the FDA’s Division of Anesthesia and Analgesia Products, told the panel. “The division is not asking you if you can approve this for the whole world of chronic pain. Based on our current thinking, they have not done enough studies in the entire population to warrant that indication.”

Through last year, about 6.5 percent of Cymbalta prescriptions were for headaches and nerve pain, including “chronic pain syndrome,” and 7 percent were for diseases of the musculoskeletal system, including arthritis and back pain, the FDA staff said in a report released this week. While companies can’t market drugs without the agency’s clearance, doctors can prescribe them for so-called off-label uses.

“People who have chronic pain very often have depression as well, so something that can treat both is just added benefit,” said Kelly Posner, director of the Center of Suicide Risk Assessment at Columbia University, in a phone interview.

Patients with chronic pain usually first try acetaminophen and ibuprofen. Older antidepressants known as tricyclics are also recommended in clinical guidelines, though they aren’t approved for chronic pain. Doctors try to limit use of oxycodone, hydrocodone and other opiate narcotics because they can be misused or lead to addiction.

Cymbalta was cleared by the FDA in 2004 for adults with major depression. Approval was extended to treating nerve pain in diabetics, generalized anxiety disorder and fibromyalgia, a condition characterized by chronic fatigue and muscle and joint pain. The drug carries warnings about potential liver risks, low blood pressure, seizures, loss of consciousness, and suicidal behavior in children and young adults.

Investors and analysts have looked to Lilly’s experimental Alzheimer’s disease therapies to replace revenue lost to generic copies of Cymbalta and Zyprexa. The company said Aug. 17 that it would abandon one of the Alzheimer’s drugs in late-stage clinical trials because it was associat


Post a comment to this story

We reserve the right to remove any post that we feel is obscene, profane, vulgar, racist, sexually explicit, abusive, or hateful.
You are legally responsible for what you post and your anonymity is not guaranteed.
Posts that insult, defame, threaten, harass or abuse other readers or people mentioned in IBJ editorial content are also subject to removal. Please respect the privacy of individuals and refrain from posting personal information.
No solicitations, spamming or advertisements are allowed. Readers may post links to other informational websites that are relevant to the topic at hand, but please do not link to objectionable material.
We may remove messages that are unrelated to the topic, encourage illegal activity, use all capital letters or are unreadable.

Messages that are flagged by readers as objectionable will be reviewed and may or may not be removed. Please do not flag a post simply because you disagree with it.

Sponsored by

facebook - twitter on Facebook & Twitter

Follow on TwitterFollow IBJ on Facebook:
Follow on TwitterFollow IBJ's Tweets on these topics:
Subscribe to IBJ
  1. I am a Lyft driver who is a licensed CDL professional driver. ALL Lyft drivers take pride in providing quality service to the Indianapolis and surrounding areas, and we take the safety of our passengers and the public seriously.(passengers are required to put seat belts on when they get in our cars) We do go through background checks, driving records are checked as are the personal cars we drive, (these are OUR private cars we use) Unlike taxi cabs and their drivers Lyft (and yes Uber) provide passengers with a clean car inside and out, a friendly and courteous driver, and who is dressed appropriately and is groomed appropriately. I go so far as to offer mints, candy and/or small bottle of water to the my customers. It's a mutual respect between driver and passenger. With Best Regards

  2. to be the big fish in the little pond of IRL midwest racin' when yer up against Racin' Gardner

  3. In the first sentance "As a resident of one of these new Carmel Apartments the issue the local governments need to discuss are build quality & price." need a way to edit

  4. As a resident of one of these new Carmel Apartments the issue the local governments need to discuss is build quality & price. First none of these places is worth $1100 for a one bedroom. Downtown Carmel or Keystone at the Crossing in Indy. It doesn't matter. All require you to get in your car to get just about anywhere you need to go. I'm in one of the Carmel apartments now where after just 2.5 short years one of the kitchen cabinet doors is crooked and lawn and property maintenance seems to be lacking my old Indianapolis apartment which cost $300 less. This is one of the new star apartments. As they keep building throughout the area "deals" will start popping up creating shoppers. If your property is falling apart after year 3 what will it look like after year 5 or 10??? Why would one stay here if they could move to a new Broad Ripple in 2 to 3 years or another part of the Far Northside?? The complexes aren't going to let the "poor" move in without local permission so that's not that problem, but it the occupancy rate drops suddenly because the "Young" people moved back to Indy then look out.

  5. Why are you so concerned about Ace hardware? I don't understand why anyone goes there! Every time ive gone in the past, they don't have what I need and I end up going to the big box stores. I understand the service aspect and that they try to be helpful but if they are going to survive I think they might need to carry more specialty parts.